Samsung Biologics will focus on scaling up its production and research sites for the coming decades with an aim of venturing into new drug formats like vaccines and developing new medication beyond its core biosimilar business.
Samsung Biologics’ new chief executive John Rim officially took office on Wednesday, following the approval of the company’s board of directors on the same day. His appointment marks the first change in the company's leadership in its 9-year history.
Samsung Biologics named Executive Vice President John Rim as the new CEO of the biopharmaceutical affiliate of Samsung on Tuesday, acknowledging his experience at well-known multinational drug makers.
Samsung Biologics is mass producing Eli Lilly’s antibody treatment for the new coronavirus, the Korean biopharmaceutical company said Tuesday.
Samsung Biologics signed a contract development organization (CDO) deal with GeneQuantum, a Chinese biotech venture, the Korean company said Monday.
Samsung Biologics opened its first overseas research & development (R&D) center in San Francisco on Thursday. The 500-acre research unit is dedicated to the bio-pharmaceutical company’s contract development organization (CDO) business.
Samsung Biologics reported 56.1 billion won ($49.5 million) in net profit for the third quarter, a 27 percent on-year increase.
In the early 2000s, Korea’s largest conglomerates Samsung, LG and SK were all executing massive investment plans in the field of biopharmaceuticals — a highly unfamiliar realm to Koreans at the time.
Samsung Biologics has signed a three-year supply deal worth $330.8 million with British pharmaceutical firm AstraZeneca. Under the contract deal, Samsung Biologics will produce drug substances and products for AstraZeneca through Dec. 2023.
Samsung Biologics will build its largest factory in Songdo, Incheon, with an investment totaling 1.74 trillion won ($1.47 billion). This will be the company’s fourth plant, all in Incheon's Songdo District.